Press Releases

Month Year

Month Year

Jan 17, 2023

FDA approves Adacel® for immunization during pregnancy to help protect young infants against pertussis
Dec 21, 2022

Positive Dupixent® (dupilumab) Phase 3 results in adults and adolescents with eosinophilic esophagitis published in the New England Journal of Medicine

Dupixent 300 mg weekly showed significant histological disease remission and improvement in symptoms of the disease compared to placebo
Dec 2, 2022

Sanofi to showcase new data from oncology portfolio spanning marketed products and investigational compounds at ASH 2022

Four Sarclisa® (isatuximab-irfc) oral presentations and 11 posters featuring cutting-edge investigational and marketed therapies to be presented
Nov 30, 2022

Sanofi to present new clinical data reinforcing novel therapies across rare blood disorders at ASH 2022
Oct 6, 2022

Sanofi US enters into co-promotion agreement with Provention Bio, Inc. to launch teplizumab, an investigational disease-modifying therapy for type 1 diabetes
Sep 28, 2022

Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis

Dupixent significantly reduced itch and skin lesions compared to placebo in direct-to-Phase 3 program consisting of two pivotal trials
Sep 8, 2022

Dupixent® (dupilumab) late-breaking Phase 3 data at EADV 2022 showed significant improvements in signs and symptoms of prurigo nodularis
Aug 31, 2022

Xenpozyme™ (olipudase alfa-rpcp) approved by FDA as first disease-specific treatment for ASMD (non-CNS manifestations)
Aug 30, 2022

FDA grants priority review to efanesoctocog alfa for people with hemophilia A
Aug 26, 2022

Sanofi higher dose flu vaccines preferentially recommended for adults 65+ in CDC Morbidity and Mortality Weekly Report

Show per page

Print
Email page
RSS